Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

Luciana Franco Do Prado De Carvalho,Esper George Kallas,Publio Cesar Cavalcante Viana,Artur Katz,Lucila Soares Da Silva Rocha,Manuel Santos Da Cruz Neto,Andrea Kazumi Shimada

doi:10.4236/alc.2015.44007

Luciana Franco Do Prado De Carvalho, Esper George Kallas + Show 5 more

Open Access

https://doi.org/10.4236/alc.2015.44007

Copy DOI

Journal: Advances in Lung Cancer	Publication Date: Jan 1, 2015
Citations: 16	License type: CC BY 4.0

Affiliation: Hospital Sírio-Libanês

Abstract

Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ROS1. In a safety database trial, it was suggested an association of Crizotinib with the development of renal cyst in patients with non-small-cell lung cancer (NSCLC). Aim: To report an uncommon side effect of Crizotinib in a patient with NSLC. Case Presentation: We report the case of a 68-year-old woman with NSCLC who developed bilateral progressive aseptic renal abscesses during Crizotinib treatment. Conclusion: Further studies may be necessary to determinate the risk of renal cyst development and the management of these complications.

Highlights

The activating mutation or translocation of anaplastic lymphoma kinase gene (ALK) is present at 2% to 7% ofHow to cite this paper: Carvalho, L.F.P., Shimada, A.K., Cruz Neto, M.S., Rocha, L.S., Viana, P.C.C., Kallas, E.G. and Katz, A. (2015) Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment
Phase 3 trials showed that the inhibition of ALK with Crizotinib in lung tumors with the ALK rearrangement resulted in benefit in progression-free survival, symptom control and response rate in both first and second line with response rate of 68% - 75% and progression-free survival of 10.9 months [8] [9]
We report a case of a patient with non-small-cell lung cancer (NSCLC) ALK translocation who developed multiple, bilateral aseptic renal abscesses on treatment with Crizotinib

Summary

Introduction

The activating mutation or translocation of anaplastic lymphoma kinase gene (ALK) is present at 2% to 7% of. (2015) Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment. PROFILE 1005 [11], a phase II trial, reported the first two cases of renal cyst during Crizotinib treatment. Among 1205 patients who received Crizotinib in the two largest Crizotinib clinical trials (PROFILE 1005 [11] and PROFILE 1007 [9]), 24 patients (2%) had adverse effects of treatment-related renal cysts [12]. 17 patients had renal cysts reported as serious adverse event [12]. We report a case of a patient with NSCLC ALK translocation who developed multiple, bilateral aseptic renal abscesses on treatment with Crizotinib

Case Report

Discussion

Findings

Conclusion